Available EXPANDED_ACCESS NCT03746899

Expanded Access for Treatment Use of PLX-PAD in Critical Limb Ischemia (CLI)

Expanded Access to Provide Intramuscular Injections of PLX-PAD for the Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization

Sponsor: WideTrial, Inc.

Conditions Critical Limb Ischemia (CLI)

Interventions PLX-PAD

Updated 5 times since 2018 Last updated: Jan 7, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Critical Limb Ischemia (CLI), this trial is ongoing. The trial is conducted by WideTrial, Inc. and has accumulated 5 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Available
Jul 2024 — Sep 2024 [monthly]

Available
Jan 2021 — Jul 2024 [monthly]

Available
Feb 2019 — Jan 2021 [monthly]

Available
Dec 2018 — Feb 2019 [monthly]

Available

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

WideTrial, Inc.

Data source: WideTrial, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.